Ignite Creation Date:
2025-12-26 @ 11:13 AM
Ignite Modification Date:
2025-12-26 @ 11:13 AM
Study NCT ID:
NCT05593328
Status:
COMPLETED
Last Update Posted:
2025-01-10
First Post:
2022-10-20
Is NOT Gene Therapy:
False
Has Adverse Events:
False
Brief Title:
Study of Onvansertib in Combination With FOLFIRI and Bevacizumab Versus FOLFIRI and Bevacizumab for Second Line Treatment of Metastatic Colorectal Cancer in Participants With a Kirsten Rat Sarcoma Virus Gene (KRAS) or Neuroblastoma-RAS (NRAS) Mutation
Sponsor:
Cardiff Oncology
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2023-03-17
Start Date Type:
ACTUAL
Primary Completion Date:
2024-12-09
Primary Completion Date Type:
ACTUAL
Completion Date:
2024-12-09
Completion Date Type:
ACTUAL
First Submit Date:
2022-10-20
First Submit QC Date:
None
Study First Post Date:
2022-10-25
Study First Post Date Type:
ACTUAL
Results First Submit Date:
None
Results First Submit QC Date:
None
Results First Post Date:
None
Results First Post Date Type:
None
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2025-01-09
Last Update Post Date:
2025-01-10
Last Update Post Date Type:
ACTUAL